
Asst Professor @unmchemeonc. Alumni @uthsaim @stanford Lymphoma/MRD/CAR-T/AlloSCT #Womeninmedicine 👨👩👦🇮🇳🇺🇸
USA
Joined December 2017
- Tweets322
- Following575
- Followers395
- Likes1.8K
Thanks @DrJulieVose! UNMC is one of the few institutes that already incorporates MRD testing in our SOP for lymphoma patients. Looking forward to build upon more knowledge and clarity regarding MRD testing in lymphoma.
Dr. Snegha Ananth presenting important data on ctDNA post CART and predictive values for relapse. #ASH2025 Great job! @NebraskaMed @UNMCHemeOnc
Thank you @lymphomaphilia for the shoutout. Excited to take this further with our IIT. #ASH25
Dr. Ananth rocks the stage with data from her time at Stanford questioning whether we “need” PET/CT post CAR-T in LBCL if uMRD6 at D=14!
Great presentation, UNMC is lucky have her as faculty!
1
197
Presented real-world ClonoSEQ MRD kinetics after axi-cel and liso-cel at #ASH25, exploring MRD-guided surveillance . Happy to build on a work started as a @StanfordBMT_CT fellow and now continuing to expand as a faculty. Slides in thread..(#1/4)
D14 MRD stratified outcomes after axi-cel; detectable MRD had ~3.5 mo PFS. A potential window for consolidation trials. Need larger numbers for liso-cel.(#3/4)
1
59
Simulation suggests early MRD- pts rarely relapse, supporting MRD-guided surveillance with PET limited to early MRD+, MRD conversion, or symptoms. Extra-nodal/small lesions still warrant PET. Encouraging for prospective evaluation.(#4/4)
46
Snegha Ananth retweeted
HLH (“IEC-HS”) is hard to distinguish from CRS and other diagnoses after CAR T cells, Also, cytopenias (ICAHT) are common after CAR T and stem cell boost is the only known effective solution. Interestingly, boost was seen to fuel the fire of IEC-HS here: ashpublications.org/bloodadv…
Our report on 2 cases of recurrent IEC-HS after Cilta-cel: Inflammation begets inflammation. Identify early cytopenia etiology before stem cell boost & monitor for recurrence. Better bridging options may reduce severe toxicities. @SurbhiSidanaMD
ashpublications.org/bloodadv…
Lucky to be a part of this team! 😇
@UNMCHemeOnc @Buffett Cancer Center Lymphoma Team meeting prior to #ICML25 ! Working on the next great clinical trial!
4
252
Presented my ctDNA work in lymphoma this week at #ICML2025! Clonoseq assay shows prognostic value as early as day 14 and helps clarify PET scan ambiguity in the post–Axi-cel setting. More data pending! Poster number 427. Thanks to my mentor Dr. Matthew Frank from @StanfordBMT_CT
Presenting my Stanford work at #EHA2025 in the beautiful city of Milan. Thanks to @MelodySmithMD and @LoriMuffly mentorship - my first experience working with correlative research in this innovative trial combining allogeneic transplant and Allo-CAR T-cell therapy for B-ALL.
I used to give my patients a generic “lead a healthy lifestyle” during/after cancer treatment and sometimes felt like I wasn’t truly helping.
Now I can confidently say: it matters. A healthy lifestyle is key to recovery, resilience, and reducing recurrence.
Just brand it “Exercizumab!” 😃
In all seriousness, I have been recommending exercise during & after treatment to all my patients who are able to.
Great to have Level 1 evidence supporting this strategy.
Now need systematic change to upscale & implement.
#ASCO25
Snegha Ananth retweeted
New malignancies and nonrelapse mortalities were rare, occurring in 4 and 2 patients each, and none was related to axi-cel. ow.ly/1MGx50VTZy3 #cartcell #cart #lymsm #lymphoma
Snegha Ananth retweeted
Listen to @crdangelo9 and @SneghaAnanth, both from @UNMC @NebraskaMed, and Dr. Kailash Mosalpuria at NHO to talk about #lymphoma at #NebraskaHeme25 on Apr 12! Session chair: Dr. Mehmet Sitki Copur (@MLHealthcare) Register NOW: education.binayfoundation.or… #MedTwitter #MedX #MedEd
Congratulations Dr. Bharadwaj and grateful to Dr. Weng for leading this fellowship. One of the best experiences I’ve had in my career :)
Nice to see this re: @StanfordBMT_CT BMT/CT fellowship program (Bharadwaj @LMikkMD @MelodySmithMD et al)
Now >17 years of training physicians (many initially on visa) to become academic BMT/CT experts and further advance our field 👏
Including @hemedoc!
link.springer.com/article/10…
Long awaited paper Nivo-AVD in frontline advanced cHL is here @NEJM
my take on Nivo-AVD data- a short tweetorial 🧵.
ps.. I'm not being paid by BMS and have no COI except that we treated ~30 patients on this trial at my center
nejm.org/doi/full/10.1056/NE…
1
341
My first month as an attending at @UNMCHemeOnc has been an incredible experience, thanks to an amazing and welcoming team! Grateful to work alongside @DrJulieVose and everyone here (including the photobombers 😉)—@LightTheNight by @LLSusa
Graduated from @StanfordBMT_CT – marking the end of my 15-year journey of medical education. Like a bamboo shoot that has spent years preparing, I'm now ready to grow and learn at my first ever job! 🌱
Snegha Ananth retweeted
@TomBmt133 asked, now that MRD is accepted endpoint for accelerated approvals, how do harmonize MRD across clinical trials? Here is a start: International harmonization in performing and reporting MRD in MM trials | Leukemia nature.com/articles/s41375-0…
Snegha Ananth retweeted
Liso-cel FDA approved today for R/R mantle cell lymphoma! Great to have an option with less high-grade CRS and ICANS. #lymsm #celltherapy #ASCO23
onclive.com/view/fda-approve… – at Colorado, USA






























